“Committed to Improving Human Health Through Innovative Technology”
“Sustainable Growth in Global Healthcare Market”
CMG Pharmaceutical pursues sustainable growth in the global healthcare market through R&D-driven technological
innovation under the clear mission of contributing to healthy life of humanity through innovative technology.
In particular, the U.S. FDA approval of ‘Mezofy™,’ the world’s first oral film treatment for schizophrenia approved as a
modified dosage form, marks a significant milestone for a mid-sized pharmaceutical company, an accomplishment that would
not have been possible without the dedication of our employees and cooperation from our partners.
Building on this achievement, CMG Pharmaceuticals will continue to enhance global competitiveness while strengthening
the foundation for its growth into one of Korea’s leading pharmaceutical companies.
We also remain focused on sustainable growth through our innovative corporate culture, stringent quality management
systems, and our extensive domestic and global collaboration network of CHA group.
We extend our sincere gratitude to our shareholders, customers, investors, business partners, and employees for the
continued trust and support throughout CMG Pharmaceuticals’ journey.